Remibrutinib for Chronic Hives

Who can receive remibrutinib for chronic spontaneous urticaria?

Rhapsido was among the medicines recommended for authorization at the European Medicines Agency's February 23–26 meeting. That recommendation was a scientific opinion; the subsequent EU marketing authorization followed on April 23. These are earlier regulatory milestones, rather than an approval announced on October 14. [EMA meeting highlights](https://www.ema.europa.eu/is/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-february-2026). [EMA authorization record](https://www.ema.europa.eu/en/medicines/human/EPAR/rhapsido).

Chronic spontaneous urticaria causes recurrent hives, itching or swelling without an obvious external trigger for at least six weeks. Remibrutinib blocks Bruton's tyrosine kinase, an enzyme involved in signaling that promotes the release of histamine and other inflammatory substances. This provides a different treatment mechanism for persistent symptoms. Treatment requires a prescription and, under the European product guidance, should begin with a clinician experienced in diagnosing and treating the condition. [EMA medicine overview](https://www.ema.europa.eu/en/medicines/human/EPAR/rhapsido).

How much did remibrutinib improve hives in clinical trials?

The REMIX-1 and REMIX-2 trials studied people whose symptoms persisted despite second-generation H1 antihistamines. Researchers compared remibrutinib with placebo using UAS7, a weekly itch-and-hive score ranging from zero to 42. At week 12, a score of zero occurred in 31.1% versus 10.5% of participants in REMIX-1 and 27.9% versus 6.5% in REMIX-2. Both trials also showed greater average symptom-score improvements with remibrutinib. [REMIX trial publication](https://www.nejm.org/doi/full/10.1056/NEJMoa2408792).

These findings support meaningful symptom control, but a zero score during treatment does not establish a permanent cure. Most treated participants had not reached that endpoint by week 12. Because the trials compared remibrutinib with placebo, they cannot establish superiority over another active treatment, such as omalizumab. The studies were funded by Novartis, the medicine's manufacturer, a relevant disclosure when assessing the evidence. [Trial methods, results and funding](https://www.nejm.org/doi/full/10.1056/NEJMoa2408792).

What safety issues should patients discuss before treatment?

The FDA's trial summary reports bleeding-related adverse reactions in 9% of remibrutinib recipients compared with 2% receiving placebo. This grouped category included bruising, pinpoint skin bleeding and nosebleeds, among other events; it should not be interpreted as a 9% rate of major hemorrhage. Other reported adverse reactions included upper respiratory symptoms, headache, nausea and abdominal pain. [FDA trial safety summary](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshot-rhapsido).

The U.S. prescribing information warns that medicines affecting clotting can further increase bleeding risk. It also identifies important drug interactions, advises avoiding treatment in hepatic impairment and recommends avoiding live vaccines during therapy. Planned surgery or invasive procedures require a clinician-directed interruption plan. Patients should therefore provide a complete medication list and discuss procedures and vaccinations before treatment begins. An oral formulation makes administration different from an injection, but does not remove the need for individualized safety assessment. [Rhapsido prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5e89bff-6ced-4165-acc5-fb13136b3a3d).